- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02056600
BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone.
May 7, 2014 updated by: LG Life Sciences
A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of the Combination of Gemigliptin/Metformin HCl Sustained Release 50/1000mg in Comparison to Each Component Gemigliptin 50mg and Metformin HCl Extended Release 1000mg Administered in Healthy Male Volunteers
This study is to evaluate the safety/tolerability and pharmacokinetics of the combinations of gemigliptin 50mg and metformin HCl extended release 1000mg in comparison to each component administered in healthy male volunteers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Asan Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy male adults at age between 20 to 45 at the time of the screening
- ThoseSubjects whose BMI measurement at screening visit is between 18 and 27 kg/m2
- Subjects with fasting plasma glucose (FPG) of 70-125 mg/dL at screening visit
- Subject who has voluntarily decided to participate in this clinical trial and onsented in writing
Exclusion Criteria:
- Subjects who have a past or present clinically significant disease such as hepatic, renal, gastrointestinal, respiratory, musculoskeletal, endocrine, neurological, hemato-oncological, or cardiovascular disorder
- Subjects who have a past history of gastrointestinal disease (e.g. Crohn's disease, ulcer, etc.) or surgery (however, simple appendectomy and hernioplasty are not included) that can affect the absorption of drugs
- Subjects with a medical history of allergic reaction to other drugs including the investigational products or clinically significant hypersensitivity reaction
- Subjects who have a history of drug abuse
- Subjects who have shown positive reaction to drugs that may be abused from a urine drug screening
- Subjects who took other investigational product in other trials within 90 days before the first administration of this investigational product
- Subjects who had whole blood donation within 60 days or component blood donation within 30 days before the first administration of the investigational product, or transfusion within 30 days before the first administration
- Subjects who have taken a drug which is expected to have an effect on the clinical trial within 14 days before the date of the first administration of the investigational product or have had any food that is expected to have an effect on the clinical trial within 7 days (e.g. drinks containing caffeine, grapefruit juice, etc.)
- Subjects who have had alcohol containing drinks 3 times or more per week within one month before the screening visit or cannot abstain from drinking after completing the informed consent form for the participation in the study to the end of the clinical trial
- Subjects who have smoker more than 10 cigarettes per day within the recent one month at the screening visit or cannot refrain from smoking the clinical trial period
- In the vital signs measured in sitting position at the screening visit, subjects who have showed a systolic blood pressure of < 90 mmHg or > 145 mmHg, a diastolic blood pressure of > 95 mmHg or < 60 mmHg) , or a pulse rate of > 110 bpm or < 40 bpm
- Subjects who showed the following findings in the tests conducted during the screening period:
- In excess of 1.5 times the upper normal limit (UNL) in hepatic enzyme (AST and ALT) values
- The creatinine clearance calculated by Cockcroft-Gault equation is 80 mL/min or less
- Positive result in serum test (hepatitis type B test, hepatitis type C test, Human Immunodeficiency Virus (HIV) test, syphilis test)
- QTc > 450 msec in ECG or a clinically significant abnormal rhythm
- Subjects who are considered to be unsuitable in conducting the clinical trial for other reason at the principal investigator's discretionary judgment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: G+M
Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg
|
Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
|
Experimental: C
Combination of gemigliptin50mg/metformin HCl sustained release 1000mg
|
Administration of combination of gemigliptin 50mg/metformin HCl sustained release 1000mg, for 1day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUClast
Time Frame: up to 48h post-dose
|
To evaluate AUClast of gemigliptin and metformin
|
up to 48h post-dose
|
Cmax
Time Frame: up to 48h post-dose
|
To evaluate Cmax of gemigliptin and metformin
|
up to 48h post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2014
Primary Completion (Actual)
April 1, 2014
Study Completion (Actual)
May 1, 2014
Study Registration Dates
First Submitted
February 5, 2014
First Submitted That Met QC Criteria
February 5, 2014
First Posted (Estimate)
February 6, 2014
Study Record Updates
Last Update Posted (Estimate)
May 8, 2014
Last Update Submitted That Met QC Criteria
May 7, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LG-DMCL004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on gemigliptin and metformin HCl extended release
-
LG Life SciencesUnknown
-
LG Life SciencesCompleted
-
LG Life SciencesCompleted
-
LG ChemCompletedHealthy Male VolunteersKorea, Republic of
-
LG Life SciencesCompletedType 2 DiabetesKorea, Republic of
-
LG ChemUnknown
-
UConn HealthCompletedAging | Vaccine Response Impaired | Age-Related ImmunodeficiencyUnited States
-
Johns Hopkins UniversityBaylor College of Medicine; National Heart, Lung, and Blood Institute (NHLBI); Temple UniversityNot yet recruitingAsthma | Overweight and Obesity | Asthma Chronic
-
University of ArizonaNational Cancer Institute (NCI)RecruitingOral Leukoplakia | ErythroplakiaUnited States, Canada
-
National Cancer Institute (NCI)RecruitingLung CarcinomaUnited States, Canada